Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating in a research report issued on Thursday. They presently have a $40.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $107.00. Leerink Swann’s price objective suggests a potential upside of 16.72% from the company’s current price.
ALNY has been the subject of several other reports. Jefferies Group lifted their price target on shares of Alnylam Pharmaceuticals from $80.00 to $86.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Needham & Company LLC reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 13th. JMP Securities reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, July 10th. Janney Montgomery Scott assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They set a “neutral” rating and a $74.00 price objective for the company. Finally, Credit Suisse Group AG reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Thursday. Alnylam Pharmaceuticals has a 52 week low of $33.16 and a 52 week high of $110.75. The firm’s market capitalization is $2.94 billion. The company has a 50-day moving average of $70.69 and a 200-day moving average of $66.05.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. During the same period in the previous year, the firm posted ($0.85) earnings per share. The business’s revenue was up .2% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.00% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares during the period. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock valued at $298,843,000 after buying an additional 182,614 shares during the period. Baillie Gifford & Co. raised its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock valued at $188,125,000 after buying an additional 10,317 shares during the period. Dodge & Cox acquired a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $139,650,000. Finally, State Street Corp raised its stake in Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock valued at $121,832,000 after buying an additional 258,984 shares during the period. 85.96% of the stock is currently owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.